These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37844755)

  • 81. Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling.
    Qian Z; Zhao J
    J Microbiol Biotechnol; 2022 Nov; 32(11):1406-1415. PubMed ID: 36330745
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
    Ferri N; Ruscica M
    Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
    Krysa JA; Ooi TC; Proctor SD; Vine DF
    J Nutr; 2017 Apr; 147(4):473-481. PubMed ID: 28179493
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver.
    Wang Z; Yao T; Song Z
    Alcohol Clin Exp Res; 2010 Mar; 34(3):471-8. PubMed ID: 20028367
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
    Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
    [TBL] [Abstract][Full Text] [Related]  

  • 87. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).
    Ben-Naim L; Khalaila I; Papo N
    Protein Eng Des Sel; 2022 Feb; 35():. PubMed ID: 35174858
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.
    Park SW; Moon YA; Horton JD
    J Biol Chem; 2004 Nov; 279(48):50630-8. PubMed ID: 15385538
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].
    Wu YX; Wang Y
    Yi Chuan; 2020 Oct; 42(10):965-978. PubMed ID: 33229322
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture.
    Mbikay M; Sirois F; Simoes S; Mayne J; Chrétien M
    FEBS Open Bio; 2014; 4():755-62. PubMed ID: 25349780
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
    Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
    Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.
    Jia YJ; Liu J; Guo YL; Xu RX; Sun J; Li JJ
    J Geriatr Cardiol; 2013 Dec; 10(4):361-8. PubMed ID: 24454330
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Excess phosphate promotes SARS‑CoV‑2 N protein‑induced NLRP3 inflammasome activation via the SCAP‑SREBP2 signaling pathway.
    Liu MH; Lin XL; Xiao LL
    Mol Med Rep; 2024 Mar; 29(3):. PubMed ID: 38275129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.